Travere Therapeutics Q3 2026 Earnings: FILSPARI Sales Rise 120% as Licensing Expense Weighs on Profitability

Travere Therapeutics (Nasdaq: TVTX) reported Q3 2026 U.S. net product sales of $220.2 million, up approximately 95% from $113.2 million a year earlier, while GAAP basic EPS moved to a loss of $0.55 from income of $0.29. FILSPARI generated $200.2 million in U.S. net product sales, up 120%, but a $113.1 million IPR&D expense related to the civorebrutinib licensing agreement and higher operating spending weighed on profitability. Cash, cash equivalents and marketable securities were $471.8 million at September 30, 2026.

Core Financial Results

Commercial growth was concentrated in FILSPARI, which accounted for approximately 91% of quarterly U.S. net product sales. At the same time, R&D increased as Travere advanced the Phase 3 HARMONY study and manufactured pegtibatinase, while SG&A rose to support the FSGS launch and continued IgAN commercialization.

The income statement also included the $113.1 million IPR&D expense recognized when Travere closed its exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib.

Travere’s stated non-GAAP net result excludes stock-based compensation, amortization and depreciation, and income tax. IPR&D is not among the listed exclusions, so investors should not assume the civorebrutinib charge was removed from the adjusted result.

FILSPARI Growth Was Outweighed by Licensing and Operating Costs

U.S. net product sales increased by $107.0 million year over year, but sales are not equivalent to profit and the company absorbed both a large licensing-related expense and a higher recurring cost base. Combined R&D and SG&A expenses rose by $45.8 million to $168.7 million, reflecting pipeline development and commercial investment.

As a result, Travere moved from GAAP net income of $25.7 million to a $52.3 million net loss. The adjusted result also swung from income to a loss, showing that the profitability reversal was not solely a function of the standard stock-compensation and amortization adjustments used by the company.

The $471.8 million balance of cash, cash equivalents and marketable securities provides a reference point for funding the expanding commercial and development programs. No prior-period cash balance was provided in the release for comparison.

Product and Pipeline Performance

FILSPARI Commercial and Clinical Updates

Travere received 1,932 new patient start forms during the quarter across IgAN and FSGS. The company characterized this as evidence of continued demand in IgAN and early FSGS launch momentum, although it did not disclose how the forms were divided between the two indications.

In FSGS, a post hoc analysis of 254 Phase 3 DUPLEX participants without nephrotic syndrome showed a 48% mean reduction in urine protein-to-creatinine ratio at week 108 with FILSPARI, compared with 27% for irbesartan. Complete proteinuria remission occurred in 20% and 6% of patients, respectively, while observed kidney failure rates were 2% and 8%.

For IgAN, a U.S. patent covering certain methods of using sparsentan extends into October 2037. Travere also received a notice of allowance for an FSGS method-of-use patent that is expected to provide similar coverage into October 2037 once issued.

Pegtibatinase and Civorebrutinib

Enrollment is continuing in the pivotal Phase 3 HARMONY study of pegtibatinase for classical homocystinuria. The study is expected to enroll approximately 70 patients, with topline results targeted for the second half of 2027.

For civorebrutinib, Travere plans to submit a U.S. investigational new drug application by the end of 2026. The company intends to investigate the BTK inhibitor in primary membranous nephropathy, immune-mediated FSGS and minimal change disease, with regulatory engagement expected to support subsequent late-stage development planning.

Management and Leadership Update

Management said Travere remains early in reaching the more than 100,000 addressable patients it identifies across IgAN and FSGS. Continued FILSPARI adoption and the conversion of new patient start forms into sustained product demand will therefore be important measures of commercial execution.

Bradley Campbell is scheduled to succeed Eric Dube as president and CEO and join the board on December 1, 2026. Dube is expected to remain an executive adviser through February 15, 2027, followed by a consulting role intended to support the transition.

Risks Investors Need to Watch

• Dependence on FILSPARI: The product represented approximately 91% of Q3 U.S. net product sales, creating significant exposure to its adoption, access and performance in IgAN and FSGS.
• A higher expense base: R&D and SG&A both increased by more than 35%, while the quarter also included the civorebrutinib licensing expense. Continued investment could keep profitability under pressure even if product sales grow.
• Pipeline execution and timing: Pegtibatinase’s next major clinical milestone is not expected until the second half of 2027, while civorebrutinib still requires an IND submission and further regulatory engagement before late-stage studies can begin.
• FILSPARI safety and access requirements: The drug carries boxed warnings for hepatotoxicity and embryo-fetal toxicity and is available through a restricted REMS program. Required monitoring and contraindications may add complexity to prescribing and continued use.

Summary

Travere’s Q3 2026 results showed substantial FILSPARI commercial growth, with the product generating most of the company’s U.S. net product sales. That growth did not translate into quarterly profitability because of the civorebrutinib IPR&D expense and higher R&D and commercial costs. The main items to monitor are sustained FILSPARI demand across IgAN and FSGS, the trajectory of operating expenses, HARMONY’s progress toward 2027 data and civorebrutinib’s planned regulatory transition into U.S. development.